Background: The purpose of the study was to retrospectively reassess in our institutional series at a longer follow-up the value of a systematic attempt to carry out wide resections in retroperitoneal soft tissue sarcoma.
introduction
Two series focusing on quality of surgery in retroperitoneal soft tissue sarcoma (RSTS) were published 2 years ago [1, 2] . Although the case mix was heterogeneous in the two series, both analyses came to the same conclusions, with similar figures: a frontline extended surgical approach to RSTS was associated with an improved local control.
The two papers were accompanied by an editorial [3] highlighting open issues and uncertainties, including the fact that the two retrospective analyses could not disclose any survival improvement, against a background of increased postoperative morbidity. We addressed [4] issues concerning quality of evidence of these retrospective case series analyses. We then provided details on the safety of this surgical approach [5] . Again, the editorial highlighted the lack of a survival benefit [6] . Similar concerns were raised by a recent paper from a major European group [7] . We then decided to reanalyze this series of patients consecutively treated at our institution, in order to provide further data on survival, with a longer follow-up.
patients and methods
This series included all consecutive patients affected by localized RSTS who were surgically treated with an eradicating intent at the Istituto Nazionale Tumori, Milan, Italy, from January 1985 to December 2008. This series coincides with the one previously published [2] , with the addition of patients who underwent surgery in the last part of 2007 and in 2008. Only patients first seen and surgically treated at our institution for their primary disease, or for their first relapse, were included. Patients with pediatric histologies, desmoid tumor and gastrointestinal stromal tumors were excluded. Six patients presented at our center with a concomitant evidence of distant metastases (DMs). At last, three hundred and thirty-one patients constituted the basis of the present analysis.
Clinical data were acquired from the surgical sarcoma database prospectively collected at our institution.
Surgical resections were classified only as macroscopically complete (R0 or R1) or not (R2) because the anatomic location of retroperitoneal sarcomas makes it questionable to employ a reliable microscopic assessment of margins on a retrospective review.
Simple complete excision of the tumor, or en bloc resection of the mass with adjacent organs only if directly involved, had been usually carried out until the end of 2001. From the beginning of 2002, we decided to explore an extended surgical approach. This strategy includes the following: liberal en bloc resection including nephrectomy and gastrointestinal organ resection (with the exception of pancreaticoduodenectomy and major hepatectomy, carried out only if a direct infiltration was observed); locoregional peritonectomy and miomectomy (partial/total) of the muscle of the lateral/ posterior abdominal wall (usually psoas); vascular surgery and bone resection only if vessels/bone was infiltrated, as in extremity soft tissue sarcoma (STS).
As in the previous series, a comparison between the two groups treated before 2002 (early period) and from 2002 onward (recent period) was carried out.
Other treatment modalities were used following multidisciplinary clinical decisions. However, no prospectively selected criteria were used to this end. Chemotherapy (CT) was given using standard regimens at the time or according to ongoing institutional/multi-institutional clinical studies. Radiation therapy (RT) was delivered through external beam approach with doses ranging between 36 and 65 Gy (median 50 Gy). A shift toward the preoperative setting was observed in the recent period (70% versus 40%).
Through the years, all tumors were diagnosed by at least two experienced pathologists. In the statistical analysis, histologic types were grouped as follows: liposarcomas, leiomyosarcomas, malignant peripheral-nerve sheath tumors, solitary fibrous tumors and other sarcomas.
With regard to grading, the National Federation of Centers in the Fight Against Cancer (FNCLCC) grading system [8] was applied.
Patients were prospectively followed up by clinical examination and computed tomography scan of chest and abdomen every 4 months for the first 2 years, then every 6 months for the following 3 years and yearly thereafter.
statistical methods
Standard descriptive statistics were calculated for categorical variables (i.e. frequency and percentage) and continuous variables [i.e. median and interquartile (IQ) range], as listed in the tables. The association between period of treatment (early, recent) and other variables was tested using the Wilcoxon-Mann-Whitney test for continuous variables and the chi-square test for categorical ones.
The primary end points of the study were local relapse, DMs, and overall survival (OS). They were analyzed for the entire population and separately for the two subgroups of patients operated before and after 2001. For each end point, the time to event occurrence was computed from the date of surgery at our institution to the date when the event was recorded, or censored at the date of last follow-up assessment in event-free patients. In order to make the two subgroups comparable in terms of follow-up length, we used follow-up information available up to a maximum of 60 months after surgery.
Survival curves were estimated by means of the Kaplan-Meier method and were compared by the log-rank test. Crude cumulative incidence (CCI) curves for local relapse and DM, whichever occurred first (and which included death as the competing event), were calculated in a competing risks framework as described by Marubini and Valsecchi [9] and comparisons between curves were carried out by means of the Gray test [10] . Concomitant local recurrences (LRs) and DMs were included only in the estimation of the CCI curves for DM.
Multivariate analyses were carried out by using Cox proportional hazards models. We considered the following as covariates: period of surgery (early, recent), patient's age, tumor size (£10, 10-20, >20 cm), status presentation (primary, first recurrence), histological subtype (liposarcoma, leiomyosarcoma, solitary fibrous tumor, malignant peripheral-nerve sheath tumor, other sarcoma), FNCLCC grade (GI, GII, GIII), administration of RT (no, yes) or CT (no, yes). In all analyses, patient's age was modeled as a continuous variable by using three-knot restricted cubic splines to obtain flexible fit [11] . We also included in the models interaction terms suitable for testing whether the prognostic effect of period of surgery was different among grade categories.
Statistical analyses were carried out with SAS software (SAS Institute Inc., Cary, NC) and R software (http://www.r-project.org/, 15 January 2011, date last accessed). The results were considered statistically significant whenever a two-sided P value <0.05 was achieved. Table 1 .
The median follow-up was 127 months (IQ range 108-164) for patients who underwent operation in the early period and 48 months (IQ range 32-74) for those operated more recently. During the follow-up period, 146 patients experienced local relapse (83 operated in the early period versus 63 in the recent one), which was the first event in 128 cases (77 versus 51). Overall, 74 patients developed DM (28 versus 46), which was the first event in 62 cases (18 versus 44); in 12 cases, DMs were concomitant with local relapse. As regards to mortality, 152 deaths were recorded (96 versus 56).
overall survival
The 5-year OS of patients who underwent operation in the early period was 48.2% [95% confidence interval (CI) 40.6% to 57.3%] compared with 66.5% (95% CI 59.3% to 74.5%) in the recent one ( Figure 1, panel A) . This difference was statistically significant (P = 0.009). Besides the period of treatment, the only other significant determinant for survival at multivariable analysis was histological grade (Table 2) . A trend for a better survival for patients who underwent adjuvant or neoadjuvant RT was also observed (P = 0.05).
When considering separately patients who presented with primary tumors from those who presented with first LR, the OS was 55.0% (95% CI 45.5% to 66.4%) for patients operated in the early period and 68.2% (95% CI 60.2% to 77.2%) for those operated in the recent one for primary tumor ( Figure 1 , panel B; P = 0.138), while it was 36.2% (95% CI 25.0% to 52.3%) and 59.9% (95% CI 44.7% to 80.2%), respectively, for those operated at their first LR ( Figure 1 , panel C; P = 0.052).
The interaction between grade and period of treatment was explored and found statistically significant (P = 0.008) ( Table  2) ; there was a better survival for patients operated in the recent period with regard to GI, 90.7% (95% CI 82.3% to 100.0%) versus 72.6% (95% CI 60.5% to 87.1%), and GII tumors, 74.1% (95% CI 63.6% to 86.4%) versus 37.7% (95% CI 25.3% to 56.1%), while no meaningful difference between the two periods was evident for GIII tumors, 35.4% (95% CI 23.8% to 50.0%) versus 36.4% (95% CI 25.6% to 51.6%) (Figure 2 ).
local recurrence
The 5-year CCI of LRs for patients who underwent operation in the early period was 49.3% (95% CI 41.6% to 58.4%), whereas it was 27.8% (95% CI 21.7% to 35.5%) for those in the recent period. This difference in local outcome was highly statistically significant ( Figure 3 , panel A; P < 0.0001). Besides the period of treatment, the other significant determinants of LR at multivariable analysis were status at presentation (primary versus recurrence), histological grade and subtype and administration of RT (Table 2) . Although the interaction between grade and period of treatment was not statistically significant (P = 0.403), a clear trend toward LR risk reduction was observed only in GI-GII categories.
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When considering separately patients who presented with primary tumors and those who presented with first LR, the CCI of LR for primary tumor was 39.3% (95% CI 30.3% to 51.0%) in patients operated in the early period and 20.7% (95% CI 14.5% to 29.4%) in those operated in the recent one (Figure 3 , panel B), while it was 66.7% (95% CI 54.7% to 81.3%) and 47.4% (95% CI 34.1% to 65.9%), respectively, for those operated at their first LR (Figure 3, panel C) . In both cases, differences between CCI curves were statistically significant (P = 0.004 and 0.027, respectively).
distant metastases
The 5-year CCI of DMs for patients who underwent operation in the early period was 12.1% (95% CI 7.8% to 19.0%), as compared with 24.5% (95% CI 18.6% to 32.1%) in the recent one ( Figure 4, panel A) . This difference in distant outcome was statistically significant (P = 0.005). Besides the period of treatment, the other two significant determinants of distant recurrence at multivariable analysis were histological grade and subtype ( Table 2 ). The interaction between grade and period of treatment was statistically significant (P = 0.015); no difference in terms of metastases was observed for GI and GII tumors between the two periods, whereas a highly significant increased number of patients with distant relapse was observed in the recent period for GIII tumors (Table 2) . We then looked at histological subtype and found that the predominant difference between the two periods was represented by the higher rate of metastasis in high-grade dedifferentiated liposarcoma, treated in the recent period (eight patients in the recent period developed DMs versus zero in the early period, data not shown). We looked at treatment characteristics and found no differences in administration of CT-RT between the two groups. We then looked at the histological aggressiveness of the dedifferentiated component and found it to be more pronounced in the recent period, especially in those patients who developed distant spread. It may well be that we treated in the recent period some advanced and aggressive tumors, that were not managed in the early one. None the less, the number of patients prevents to draw any conclusion on it. When considering separately patients who presented with primary tumors and those who presented with first LR, the CCI of DMs for patients with primary tumor was 16.9% (95% CI 10.6% to 26.8%) in the early period and 25.6% (95% CI 18.7% to 34.8%) in the recent one ( Figure 4 , panel B; P = 0.125), while it was 3.9% (95% CI 1.0% to 15.6%) and 20.0% (95% CI 11.7% to 34.1%), respectively, for those operated at their first LR ( Figure 4 , panel C; P = 0.011).
discussion
In our institutional series of 331 consecutive patients surgically treated for primary or first local recurrent RSTS during >20 years, we confirm that there was a 21% absolute LR reduction switching from a policy of less aggressive surgery to more extended resections, involving uninvolved adjacent organs. On a longer follow-up, we were now able to observe an 18% absolute OS improvement at 5 years. These figures compare favorably with all published retrospective series [7, [12] [13] [14] [15] [16] [17] [18] [19] (Table 3 ). This benefit is apparently confined to low-to intermediate-grade tumors, the limiting factor for high-grade ones being a remarkable DM rate.
When we first reported an improved local control rate, there was only a favorable trend in OS. This was due to the relatively short median follow-up of the recent group. We now update those results on a longer follow-up and the survival benefit is statistically significant. Although of course in a retrospective analysis, this gives further support to our hypothesis that extended surgery of RSTS may actually improve the prognosis of these patients [12] [13] [14] [15] . However, this benefit seems confined to grade I and grade II tumors, while we failed to observe a difference for patients with grade III tumors. At the moment, therefore, we can say that there is retrospective evidence that Indeed, we observed a higher number of DMs in the recent period. Of course, this has to do with the high-grade tumors. This observation was not entirely expected since it is widely felt that the main problem of RSTS is local relapse and that their tendency to metastasize is relatively low overall. Clearly, this is influenced by the number of well-differentiated liposarcomas in the RSTS series. However, it is possible that just the improvement in local control that extended surgery can achieve Annals of Oncology original articles may translate into a change in the natural history of the disease, mainly in regard to higher-grade tumors. In fact, the increase in the metastatic risk was predominantly observed in high-grade dedifferentiated liposarcomas, i.e. in a subgroup where the local control is certainly an issue. As long as local disease is better controlled, the metastatic risk may dominate at least on a medium-term follow-up. In limb STS, where local control is far better achievable, we observed that local surgical adequacy could regain relevance after the fifth year of follow-up, once the patient has 'survived the tumor biology'. Thus, our tentative conclusion is that extended surgery may be pursued also in high-grade RSTS, provided an attempt is made to concurrently address the systemic risk. In other words, for high-grade RSTS, it may be worthwhile to pursue extended surgery together with adjuvant CT.
Interestingly, the benefit applied to both patients presenting with a primary disease and those with their first recurrence following previous surgery carried out elsewhere (i.e. with a less liberal approach to resection of adjacent organs). Indeed, while a clear trend in patients operated in the recent group was observed for primary RSTS (68% versus 55% at 5 years), the trend was even more striking for patients operated on for their first LR (60% versus 36%). This may well encourage to routinely apply a policy of extended surgery also to patients whose retroperitoneal virtual 'compartment' is already violated. Thus, this could also encourage a 're-resection' policy, in the absence of evident disease, for patients already operated on through a limited resection outside referral institutions. This would parallel what is often done for limb sarcomas, but it would be best evaluated in a prospective study.
As already reported, RT was associated with a better local control and survival. It is difficult to put this observation into context. In fact, the selection of patients undergoing RT at our institution did change over time. In addition, it includes different categories of patients, in particular some undergoing limited postoperative RT (possibly to sites of lower surgical adequacy), some with pelvic STS and some receiving preoperative treatment (even within a prospective study). Radiation techniques have undergone major changes over time as well. For the moment, the observed benefit of patients who received RT adds to the rationale of prospective studies on preoperative RT, which are now under preparation.
We discussed elsewhere the main features of this extended surgery for RSTS. In essence, it implies that a higher number of adjacent uninvolved organs are deliberately resected, in an effort to reproduce what the sarcoma surgeon used to do for limb and trunk wall STS. This carries some extra morbidity, which, however, is limited. We recently showed an 18% risk of major morbidity and 3% risk of mortality in a combined series of patients treated by this approach [5] . In other words, extended surgery for RSTS is safe enough when carried out at high-volume centers, as long of course one is convinced of its survival benefit. The weaknesses of retrospective evidence are obvious, and this is the major limitation preventing such a surgical approach from becoming standard treatment. Our feeling is that it should be offered as an option for a shared decision making with the patient. This is particularly true of patients with low-to intermediate-grade RSTS. For high-grade RSTS, the combination of this surgery with adjuvant CT may be reasonable, although in the face of the uncertainty that applies also to adjuvant CT in STS. Both patients with a primary RSTS and those with a first relapse after limited surgery may benefit. The role of RT should be the subject of prospective clinical studies.
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